<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0&amp;fc=20230708114047&amp;ff=20240201011053&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0&amp;fc=20230708114047&amp;ff=20240201011053&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Thu, 01 Feb 2024 06:10:54 +0000</lastbuilddate>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Risk Estimation in Valvular Heart Disease in Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):e49. doi: 10.1016/j.jacc.2023.11.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38296409</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.023>10.1016/j.jacc.2023.11.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296409</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Anish Keepanasseril</dc:creator>
<dc:creator>Swaraj Nandini Pande</dc:creator>
<dc:creator>Santhosh Satheesh</dc:creator>
<dc:creator>Samuel C Siu</dc:creator>
<dc:creator>Rohan D'Souza</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Risk Estimation in Valvular Heart Disease in Pregnancy</dc:title>
<dc:identifier>pmid:38296409</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.023</dc:identifier>
</item>
<item>
<title>Risk Estimation in Valvular Heart Disease in Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296408/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):e47. doi: 10.1016/j.jacc.2023.10.051.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296408/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38296408</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.051>10.1016/j.jacc.2023.10.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296408</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Boban Thomas</dc:creator>
<dc:creator>Vera Vaz Ferreira</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Risk Estimation in Valvular Heart Disease in Pregnancy</dc:title>
<dc:identifier>pmid:38296408</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.051</dc:identifier>
</item>
<item>
<title>Promoting Cardiovascular Health Equity: Association of Black Cardiologists Practical Model for Community-Engaged Partnerships</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296407/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):632-636. doi: 10.1016/j.jacc.2023.11.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296407/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38296407</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.025>10.1016/j.jacc.2023.11.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296407</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Courtney Bess</dc:creator>
<dc:creator>Daphne Ferdinand</dc:creator>
<dc:creator>Paul Underwood</dc:creator>
<dc:creator>Donnell Ivy</dc:creator>
<dc:creator>Michelle A Albert</dc:creator>
<dc:creator>Anekwe Onwuanyi</dc:creator>
<dc:creator>Cassandra McCullough</dc:creator>
<dc:creator>LaPrincess C Brewer</dc:creator>
<dc:creator>Association of Black Cardiologists Community Programs Committee</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Promoting Cardiovascular Health Equity: Association of Black Cardiologists Practical Model for Community-Engaged Partnerships</dc:title>
<dc:identifier>pmid:38296407</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.025</dc:identifier>
</item>
<item>
<title>Promises and Perils of Consumer Mobile Technologies in Cardiovascular Care: JACC Scientific Statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296406/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>Direct-to-consumer (D2C) wearables are becoming increasingly popular in cardiovascular health management because of their affordability and capability to capture diverse health data. Wearables may enable continuous health care provider-patient partnerships and reduce the volume of episodic clinic-based care (thereby reducing health care costs). However, challenges arise from the unregulated use of these devices, including questionable data reliability, potential misinterpretation of information,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):611-631. doi: 10.1016/j.jacc.2023.11.024.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Direct-to-consumer (D2C) wearables are becoming increasingly popular in cardiovascular health management because of their affordability and capability to capture diverse health data. Wearables may enable continuous health care provider-patient partnerships and reduce the volume of episodic clinic-based care (thereby reducing health care costs). However, challenges arise from the unregulated use of these devices, including questionable data reliability, potential misinterpretation of information, unintended psychological impacts, and an influx of clinically nonactionable data that may overburden the health care system. Further, these technologies could exacerbate, rather than mitigate, health disparities. Experience with wearables in atrial fibrillation underscores these challenges. The prevalent use of D2C wearables necessitates a collaborative approach among stakeholders to ensure effective integration into cardiovascular care. Wearables are heralding innovative disease screening, diagnosis, and management paradigms, expanding therapeutic avenues, and anchoring personalized medicine.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296406/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38296406</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.024>10.1016/j.jacc.2023.11.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296406</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Niraj Varma</dc:creator>
<dc:creator>Janet K Han</dc:creator>
<dc:creator>Rod Passman</dc:creator>
<dc:creator>Lindsey Anne Rosman</dc:creator>
<dc:creator>Hamid Ghanbari</dc:creator>
<dc:creator>Peter Noseworthy</dc:creator>
<dc:creator>Jennifer N Avari Silva</dc:creator>
<dc:creator>Abhishek Deshmukh</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Gerhard Hindricks</dc:creator>
<dc:creator>Gregory Lip</dc:creator>
<dc:creator>Arun R Sridhar</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Promises and Perils of Consumer Mobile Technologies in Cardiovascular Care: JACC Scientific Statement</dc:title>
<dc:identifier>pmid:38296406</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.024</dc:identifier>
</item>
<item>
<title>It Is Shocking How Little We Have Talked About Cardiogenic Shock in Pediatrics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296405/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):609-610. doi: 10.1016/j.jacc.2023.11.022.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296405/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38296405</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.022>10.1016/j.jacc.2023.11.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296405</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Kurt R Schumacher</dc:creator>
<dc:creator>Carolyn Vitale</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>It Is Shocking How Little We Have Talked About Cardiogenic Shock in Pediatrics</dc:title>
<dc:identifier>pmid:38296405</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.022</dc:identifier>
</item>
<item>
<title>Clinical Presentation, Classification, and Outcomes of Cardiogenic Shock in Children</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296404/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>CONCLUSIONS: CS occurs in 26% of pediatric hospitalizations for ADHF and is independently associated with hospital mortality. A modified Society for Cardiovascular Angiography and Interventions classification for CS severity showed robust association with increasing mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):595-608. doi: 10.1016/j.jacc.2023.11.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite growing cardiogenic shock (CS) research in adults, the epidemiology, clinical features, and outcomes of children with CS are lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to describe the epidemiology, clinical presentation, hospital course, risk factors, and outcomes of CS among children hospitalized for acute decompensated heart failure (ADHF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We examined consecutive ADHF hospitalizations (&lt;21 years of age) from a large single-center retrospective cohort. Patients with CS at presentation were analyzed and risk factors for CS and for the primary outcome of in-hospital mortality were identified. A modified Society for Cardiovascular Angiography and Interventions shock classification was created and patients were staged accordingly.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 803 hospitalizations for ADHF were identified in 591 unique patients (median age 7.6 years). CS occurred in 207 (26%) hospitalizations. ADHF hospitalizations with CS were characterized by worse systolic function (P = 0.040), higher B-type natriuretic peptide concentration (P = 0.032), and more frequent early severe renal (P = 0.023) and liver (P &lt; 0.001) injury than those without CS. Children presenting in CS received mechanical ventilation (87% vs 26%) and mechanical circulatory support (45% vs 16%) more frequently (both P &lt; 0.001). Analyzing only the most recent ADHF hospitalization, children with CS were at increased risk of in-hospital mortality compared with children without CS (28% vs 11%; OR: 1.91; 95% CI: 1.05-3.45; P = 0.033). Each higher CS stage was associated with greater inpatient mortality (OR: 2.40-8.90; all P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CS occurs in 26% of pediatric hospitalizations for ADHF and is independently associated with hospital mortality. A modified Society for Cardiovascular Angiography and Interventions classification for CS severity showed robust association with increasing mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296404/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38296404</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.019>10.1016/j.jacc.2023.11.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296404</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Kriti Puri</dc:creator>
<dc:creator>Jacob C Jentzer</dc:creator>
<dc:creator>Joseph A Spinner</dc:creator>
<dc:creator>Kyle D Hope</dc:creator>
<dc:creator>Iki Adachi</dc:creator>
<dc:creator>Sebastian C Tume</dc:creator>
<dc:creator>Hari P Tunuguntla</dc:creator>
<dc:creator>Swati Choudhry</dc:creator>
<dc:creator>Antonio G Cabrera</dc:creator>
<dc:creator>Jack F Price</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Presentation, Classification, and Outcomes of Cardiogenic Shock in Children</dc:title>
<dc:identifier>pmid:38296404</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.019</dc:identifier>
</item>
<item>
<title>Innovative Methods to Tackle Longstanding Goals in Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296403/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):592-594. doi: 10.1016/j.jacc.2023.11.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296403/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38296403</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.020>10.1016/j.jacc.2023.11.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296403</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Brian R Lindman</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Innovative Methods to Tackle Longstanding Goals in Aortic Stenosis</dc:title>
<dc:identifier>pmid:38296403</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.020</dc:identifier>
</item>
<item>
<title>Large-Scale Proteomics Identifies Novel Biomarkers and Circulating Risk Factors for Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296402/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>CONCLUSIONS: These findings identify MMP12 as a potential novel circulating biomarker of AS risk and C1QTNF1 as a new putative target to prevent AS progression.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):577-591. doi: 10.1016/j.jacc.2023.11.021.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Limited data exist regarding risk factors for aortic stenosis (AS). The plasma proteome is a promising phenotype for discovery of novel biomarkers and potentially causative mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to discover novel biomarkers with potentially causal associations with AS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We measured 4,877 plasma proteins (SomaScan aptamer-affinity assay) among ARIC (Atherosclerosis Risk In Communities) study participants in mid-life (visit 3 [V3]; n = 11,430; age 60 ± 6 years) and in late-life (V5; n = 4,899; age 76 ± 5 years). We identified proteins cross-sectionally associated with aortic valve (AV) peak velocity (AVmax) and dimensionless index by echocardiography at V5 and with incident AV-related hospitalization after V3 with the use of multivariable linear and Cox proportional hazard regression. We assessed associations of candidate proteins with changes in AVmax over 6 years and with AV calcification with the use of cardiac computed tomography, replicated analysis in an independent sample, performed Mendelian randomization, and evaluated gene expression in explanted human AV tissue.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Fifty-two proteins cross-sectionally were associated with AVmax and dimensionless index at V5 and with risk of incident AV-related hospitalization after V3. Among 3,413 participants in the Cardiovascular Health Study, 6 of those proteins were significantly associated with adjudicated moderate or severe AS, including matrix metalloproteinase 12 (MMP12), complement C1q tumor necrosis factor-related protein 1 (C1QTNF1), and growth differentiation factor-15. MMP12 was also associated with greater increase in AVmax over 6 years, greater degree of AV calcification, and greater expression in calcific compared with normal or fibrotic AV tissue. C1QTNF1 had consistent potential causal effects on both AS and AVmax according to Mendelian randomization analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings identify MMP12 as a potential novel circulating biomarker of AS risk and C1QTNF1 as a new putative target to prevent AS progression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296402/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38296402</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.021>10.1016/j.jacc.2023.11.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296402</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Khaled Shelbaya</dc:creator>
<dc:creator>Victoria Arthur</dc:creator>
<dc:creator>Yimin Yang</dc:creator>
<dc:creator>Pranav Dorbala</dc:creator>
<dc:creator>Leo Buckley</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Hicham Skali</dc:creator>
<dc:creator>Line Dufresne</dc:creator>
<dc:creator>Ta-Yu Yang</dc:creator>
<dc:creator>James C Engert</dc:creator>
<dc:creator>George Thanassoulis</dc:creator>
<dc:creator>James Floyd</dc:creator>
<dc:creator>Thomas R Austin</dc:creator>
<dc:creator>Anna Bortnick</dc:creator>
<dc:creator>Jorge Kizer</dc:creator>
<dc:creator>Renata C C Freitas</dc:creator>
<dc:creator>Sasha A Singh</dc:creator>
<dc:creator>Elena Aikawa</dc:creator>
<dc:creator>Ron C Hoogeveen</dc:creator>
<dc:creator>Christie Ballantyne</dc:creator>
<dc:creator>Bing Yu</dc:creator>
<dc:creator>Josef Coresh</dc:creator>
<dc:creator>Michael J Blaha</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Large-Scale Proteomics Identifies Novel Biomarkers and Circulating Risk Factors for Aortic Stenosis</dc:title>
<dc:identifier>pmid:38296402</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.021</dc:identifier>
</item>
<item>
<title>Redefining Cardiovascular Risk Assessment as a Spectrum: From Binary to Continuous</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296401/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):574-576. doi: 10.1016/j.jacc.2023.11.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296401/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38296401</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.026>10.1016/j.jacc.2023.11.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296401</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Pier Sergio Saba</dc:creator>
<dc:creator>Sadeer Al Kindi</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Redefining Cardiovascular Risk Assessment as a Spectrum: From Binary to Continuous</dc:title>
<dc:identifier>pmid:38296401</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.026</dc:identifier>
</item>
<item>
<title>Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296400/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>CONCLUSIONS: A universal risk prediction approach performed well in persons with and without ASCVD. This approach could facilitate the transition from primary to secondary prevention by streamlining risk classification and discussion between clinicians and patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):562-573. doi: 10.1016/j.jacc.2023.11.028.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: American College of Cardiology/American Heart Association guidelines recommend distinct risk classification systems for primary and secondary cardiovascular disease prevention. However, both systems rely on similar predictors (eg, age and diabetes), indicating the possibility of a universal risk prediction approach for major adverse cardiovascular events (MACEs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors examined the performance of predictors in persons with and without atherosclerotic cardiovascular disease (ASCVD) and developed and validated a universal risk prediction model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among 9,138 ARIC (Atherosclerosis Risk In Communities) participants with (n = 609) and without (n = 8,529) ASCVD at baseline (1996-1998), we examined established predictors in the risk classification systems and other predictors, such as body mass index and cardiac biomarkers (troponin and natriuretic peptide), using Cox models with MACEs (myocardial infarction, stroke, and heart failure). We also evaluated model performance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a follow-up of approximately 20 years, there were 3,209 MACEs (2,797 for no prior ASCVD). Most predictors showed similar associations with MACE regardless of baseline ASCVD status. A universal risk prediction model with the predictors (eg, established predictors, cardiac biomarkers) identified by least absolute shrinkage and selection operator regression and bootstrapping showed good discrimination for both groups (c-statistics of 0.747 and 0.691, respectively), and risk classification and showed excellent calibration, irrespective of ASCVD status. This universal prediction approach identified individuals without ASCVD who had a higher risk than some individuals with ASCVD and was validated externally in 5,322 participants in the MESA (Multi-Ethnic Study of Atherosclerosis).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A universal risk prediction approach performed well in persons with and without ASCVD. This approach could facilitate the transition from primary to secondary prevention by streamlining risk classification and discussion between clinicians and patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296400/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38296400</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.028>10.1016/j.jacc.2023.11.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296400</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yejin Mok</dc:creator>
<dc:creator>Zeina Dardari</dc:creator>
<dc:creator>Yingying Sang</dc:creator>
<dc:creator>Xiao Hu</dc:creator>
<dc:creator>Michael P Bancks</dc:creator>
<dc:creator>Lena Mathews</dc:creator>
<dc:creator>Ron C Hoogeveen</dc:creator>
<dc:creator>Silvia Koton</dc:creator>
<dc:creator>Michael J Blaha</dc:creator>
<dc:creator>Wendy S Post</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Josef Coresh</dc:creator>
<dc:creator>Wayne Rosamond</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease</dc:title>
<dc:identifier>pmid:38296400</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.028</dc:identifier>
</item>
<item>
<title>A Post Hoc Analysis of ISCHEMIA: Are All Events Created Equal?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38296399/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 6;83(5):559-561. doi: 10.1016/j.jacc.2023.11.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38296399/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38296399</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.027>10.1016/j.jacc.2023.11.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38296399</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>J Michael DiMaio</dc:creator>
<dc:creator>Kyle A McCullough</dc:creator>
<dc:creator>R Jay Widmer</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Post Hoc Analysis of ISCHEMIA: Are All Events Created Equal?</dc:title>
<dc:identifier>pmid:38296399</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.027</dc:identifier>
</item>
<item>
<title>Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38295787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>Streptococcus anginosus (S. anginosus) was enriched in the gastric mucosa of patients with gastric cancer (GC). Here, we show that S. anginosus colonized the mouse stomach and induced acute gastritis. S. anginosus infection spontaneously induced progressive chronic gastritis, parietal cell atrophy, mucinous metaplasia, and dysplasia in conventional mice, and the findings were confirmed in germ-free mice. In addition, S. anginosus accelerated GC progression in carcinogen-induced gastric...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 22:S0092-8674(24)00006-0. doi: 10.1016/j.cell.2024.01.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Streptococcus anginosus (S. anginosus) was enriched in the gastric mucosa of patients with gastric cancer (GC). Here, we show that S. anginosus colonized the mouse stomach and induced acute gastritis. S. anginosus infection spontaneously induced progressive chronic gastritis, parietal cell atrophy, mucinous metaplasia, and dysplasia in conventional mice, and the findings were confirmed in germ-free mice. In addition, S. anginosus accelerated GC progression in carcinogen-induced gastric tumorigenesis and YTN16 GC cell allografts. Consistently, S. anginosus disrupted gastric barrier function, promoted cell proliferation, and inhibited apoptosis. Mechanistically, we identified an S. anginosus surface protein, TMPC, that interacts with Annexin A2 (ANXA2) receptor on gastric epithelial cells. Interaction of TMPC with ANXA2 mediated attachment and colonization of S. anginosus and induced mitogen-activated protein kinase (MAPK) activation. ANXA2 knockout abrogated the induction of MAPK by S. anginosus. Thus, this study reveals S. anginosus as a pathogen that promotes gastric tumorigenesis via direct interactions with gastric epithelial cells in the TMPC-ANXA2-MAPK axis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38295787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38295787</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.004>10.1016/j.cell.2024.01.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38295787</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Kaili Fu</dc:creator>
<dc:creator>Alvin Ho Kwan Cheung</dc:creator>
<dc:creator>Chi Chun Wong</dc:creator>
<dc:creator>Weixin Liu</dc:creator>
<dc:creator>Yunfei Zhou</dc:creator>
<dc:creator>Feixue Wang</dc:creator>
<dc:creator>Pingmei Huang</dc:creator>
<dc:creator>Kai Yuan</dc:creator>
<dc:creator>Olabisi Oluwabukola Coker</dc:creator>
<dc:creator>Yasi Pan</dc:creator>
<dc:creator>Danyu Chen</dc:creator>
<dc:creator>Nga Man Lam</dc:creator>
<dc:creator>Mengxue Gao</dc:creator>
<dc:creator>Xiang Zhang</dc:creator>
<dc:creator>He Huang</dc:creator>
<dc:creator>Ka Fai To</dc:creator>
<dc:creator>Joseph Jao Yiu Sung</dc:creator>
<dc:creator>Jun Yu</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice</dc:title>
<dc:identifier>pmid:38295787</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.004</dc:identifier>
</item>
<item>
<title>What Is Your Secret to Health?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38294819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 31. doi: 10.1001/jamacardio.2023.5344. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38294819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38294819</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5344>10.1001/jamacardio.2023.5344</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38294819</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Rebecca Ann Levine</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>What Is Your Secret to Health?</dc:title>
<dc:identifier>pmid:38294819</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5344</dc:identifier>
</item>
<item>
<title>Machine Learning Multicenter Risk Model to Predict Right Ventricular Failure After Mechanical Circulatory Support: The STOP-RVF Score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38294795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: Implementing routine clinical data, this multicenter cohort study derived and validated the STOP-RVF calculator as a personalized risk assessment tool for the prediction of RVF and RVF-associated all-cause mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 31. doi: 10.1001/jamacardio.2023.5372. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The existing models predicting right ventricular failure (RVF) after durable left ventricular assist device (LVAD) support might be limited, partly due to lack of external validation, marginal predictive power, and absence of intraoperative characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To derive and validate a risk model to predict RVF after LVAD implantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a hybrid prospective-retrospective multicenter cohort study conducted from April 2008 to July 2019 of patients with advanced heart failure (HF) requiring continuous-flow LVAD. The derivation cohort included patients enrolled at 5 institutions. The external validation cohort included patients enrolled at a sixth institution within the same period. Study data were analyzed October 2022 to August 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Study participants underwent chronic continuous-flow LVAD support.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: The primary outcome was RVF incidence, defined as the need for RV assist device or intravenous inotropes for greater than 14 days. Bootstrap imputation and adaptive least absolute shrinkage and selection operator variable selection techniques were used to derive a predictive model. An RVF risk calculator (STOP-RVF) was then developed and subsequently externally validated, which can provide personalized quantification of the risk for LVAD candidates. Its predictive accuracy was compared with previously published RVF scores.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The derivation cohort included 798 patients (mean [SE] age, 56.1 [13.2] years; 668 male [83.7%]). The external validation cohort included 327 patients. RVF developed in 193 of 798 patients (24.2%) in the derivation cohort and 107 of 327 patients (32.7%) in the validation cohort. Preimplant variables associated with postoperative RVF included nonischemic cardiomyopathy, intra-aortic balloon pump, microaxial percutaneous left ventricular assist device/venoarterial extracorporeal membrane oxygenation, LVAD configuration, Interagency Registry for Mechanically Assisted Circulatory Support profiles 1 to 2, right atrial/pulmonary capillary wedge pressure ratio, use of angiotensin-converting enzyme inhibitors, platelet count, and serum sodium, albumin, and creatinine levels. Inclusion of intraoperative characteristics did not improve model performance. The calculator achieved a C statistic of 0.75 (95% CI, 0.71-0.79) in the derivation cohort and 0.73 (95% CI, 0.67-0.80) in the validation cohort. Cumulative survival was higher in patients composing the low-risk group (estimated &lt;20% RVF risk) compared with those in the higher-risk groups. The STOP-RVF risk calculator exhibited a significantly better performance than commonly used risk scores proposed by Kormos et al (C statistic, 0.58; 95% CI, 0.53-0.63) and Drakos et al (C statistic, 0.62; 95% CI, 0.57-0.67).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Implementing routine clinical data, this multicenter cohort study derived and validated the STOP-RVF calculator as a personalized risk assessment tool for the prediction of RVF and RVF-associated all-cause mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38294795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38294795</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5372>10.1001/jamacardio.2023.5372</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38294795</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Iosif Taleb</dc:creator>
<dc:creator>Christos P Kyriakopoulos</dc:creator>
<dc:creator>Robyn Fong</dc:creator>
<dc:creator>Naila Ijaz</dc:creator>
<dc:creator>Zachary Demertzis</dc:creator>
<dc:creator>Konstantinos Sideris</dc:creator>
<dc:creator>Omar Wever-Pinzon</dc:creator>
<dc:creator>Antigone G Koliopoulou</dc:creator>
<dc:creator>Michael J Bonios</dc:creator>
<dc:creator>Rohan Shad</dc:creator>
<dc:creator>Adithya Peruri</dc:creator>
<dc:creator>Thomas C Hanff</dc:creator>
<dc:creator>Elizabeth Dranow</dc:creator>
<dc:creator>Theodoros V Giannouchos</dc:creator>
<dc:creator>Ethan Krauspe</dc:creator>
<dc:creator>Cyril Zakka</dc:creator>
<dc:creator>Daniel G Tang</dc:creator>
<dc:creator>Hassan W Nemeh</dc:creator>
<dc:creator>Josef Stehlik</dc:creator>
<dc:creator>James C Fang</dc:creator>
<dc:creator>Craig H Selzman</dc:creator>
<dc:creator>Rami Alharethi</dc:creator>
<dc:creator>William T Caine</dc:creator>
<dc:creator>Jennifer A Cowger</dc:creator>
<dc:creator>William Hiesinger</dc:creator>
<dc:creator>Palak Shah</dc:creator>
<dc:creator>Stavros G Drakos</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Machine Learning Multicenter Risk Model to Predict Right Ventricular Failure After Mechanical Circulatory Support: The STOP-RVF Score</dc:title>
<dc:identifier>pmid:38294795</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5372</dc:identifier>
</item>
<item>
<title>Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38294787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: In this pooled cohort study, the presence of FH variants was associated with a 2-fold higher CHD risk, even when LDL-C was only moderately elevated. The increased CHD risk appeared to be largely explained by the higher cumulative LDL-C exposure in individuals with an FH variant compared to those without. Further research is needed to assess the value of adding genetic testing to traditional phenotypic FH screening.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 31. doi: 10.1001/jamacardio.2023.5366. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Familial hypercholesterolemia (FH) is a genetic disorder that often results in severely high low-density lipoprotein cholesterol (LDL-C) and high risk of premature coronary heart disease (CHD). However, the impact of FH variants on CHD risk among individuals with moderately elevated LDL-C is not well quantified.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess CHD risk associated with FH variants among individuals with moderately (130-189 mg/dL) and severely (≥190 mg/dL) elevated LDL-C and to quantify excess CHD deaths attributable to FH variants in US adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: A total of 21 426 individuals without preexisting CHD from 6 US cohort studies (Atherosclerosis Risk in Communities study, Coronary Artery Risk Development in Young Adults study, Cardiovascular Health Study, Framingham Heart Study Offspring cohort, Jackson Heart Study, and Multi-Ethnic Study of Atherosclerosis) were included, 63 of whom had an FH variant. Data were collected from 1971 to 2018, and the median (IQR) follow-up was 18 (13-28) years. Data were analyzed from March to May 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: LDL-C, cumulative past LDL-C, FH variant status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Cox proportional hazards models estimated associations between FH variants and incident CHD. The Cardiovascular Disease Policy Model projected excess CHD deaths associated with FH variants in US adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 21 426 individuals without preexisting CHD (mean [SD] age 52.1 [15.5] years; 12 041 [56.2%] female), an FH variant was found in 22 individuals with moderately elevated LDL-C (0.3%) and in 33 individuals with severely elevated LDL-C (2.5%). The adjusted hazard ratios for incident CHD comparing those with and without FH variants were 2.9 (95% CI, 1.4-6.0) and 2.6 (95% CI, 1.4-4.9) among individuals with moderately and severely elevated LDL-C, respectively. The association between FH variants and CHD was slightly attenuated when further adjusting for baseline LDL-C level, whereas the association was no longer statistically significant after adjusting for cumulative past LDL-C exposure. Among US adults 20 years and older with no history of CHD and LDL-C 130 mg/dL or higher, more than 417 000 carry an FH variant and were projected to experience more than 12 000 excess CHD deaths in those with moderately elevated LDL-C and 15 000 in those with severely elevated LDL-C compared with individuals without an FH variant.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this pooled cohort study, the presence of FH variants was associated with a 2-fold higher CHD risk, even when LDL-C was only moderately elevated. The increased CHD risk appeared to be largely explained by the higher cumulative LDL-C exposure in individuals with an FH variant compared to those without. Further research is needed to assess the value of adding genetic testing to traditional phenotypic FH screening.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38294787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38294787</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5366>10.1001/jamacardio.2023.5366</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38294787</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yiyi Zhang</dc:creator>
<dc:creator>Jacqueline S Dron</dc:creator>
<dc:creator>Brandon K Bellows</dc:creator>
<dc:creator>Amit V Khera</dc:creator>
<dc:creator>Junxiu Liu</dc:creator>
<dc:creator>Pallavi P Balte</dc:creator>
<dc:creator>Elizabeth C Oelsner</dc:creator>
<dc:creator>Sami Samir Amr</dc:creator>
<dc:creator>Matthew S Lebo</dc:creator>
<dc:creator>Anna Nagy</dc:creator>
<dc:creator>Gina M Peloso</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Jerome I Rotter</dc:creator>
<dc:creator>Cristen Willer</dc:creator>
<dc:creator>Eric Boerwinkle</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Pamela L Lutsey</dc:creator>
<dc:creator>Myriam Fornage</dc:creator>
<dc:creator>Donald M Lloyd-Jones</dc:creator>
<dc:creator>Lifang Hou</dc:creator>
<dc:creator>Bruce M Psaty</dc:creator>
<dc:creator>Joshua C Bis</dc:creator>
<dc:creator>James S Floyd</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Nancy L Heard-Costa</dc:creator>
<dc:creator>April P Carson</dc:creator>
<dc:creator>Michael E Hall</dc:creator>
<dc:creator>Stephen S Rich</dc:creator>
<dc:creator>Xiuqing Guo</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>Sarah D de Ferranti</dc:creator>
<dc:creator>Andrew E Moran</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol</dc:title>
<dc:identifier>pmid:38294787</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5366</dc:identifier>
</item>
<item>
<title>Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38291599/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>CONCLUSIONS: Systolic BPV is a strong predictor of CV outcome, even in those with controlled SBP. The long-term benefits of amlodipine-based treatment compared with atenolol-based treatment in reducing CV events appear to be primarily mediated by an effect on systolic BPV during the trial period.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 31:ehad814. doi: 10.1093/eurheartj/ehad814. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Visit-to-visit systolic blood pressure variability (BPV) is an important predictor of cardiovascular (CV) outcomes. The long-term effect of a period of blood pressure (BP) control, but with differential BPV, is uncertain. Morbidity and mortality follow-up of UK participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure-Lowering Arm has been extended for up to 21 years to determine the CV impact of mean systolic blood pressure (SBP) control and BPV during the trial, and amongst those allocated to amlodipine- and atenolol-based treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Eight thousand five hundred and eighty hypertensive participants (4305 assigned to amlodipine ± perindopril-based and 4275 to atenolol ± diuretic-based treatment during the in-trial period (median 5.5 years) were followed for up to 21 years (median 17.4 years), using linked hospital and mortality records. A subgroup of participants (n = 2156) was followed up 6 years after the trial closure with a self-administered questionnaire and a clinic visit. In-trial mean SBP and standard deviation of visit-to-visit SBP as a measure of BPV, were measured using >;100 000 BP measurements. Cox proportional hazard models were used to estimate the risk [hazard ratios (HRs)], associated with (i) mean with SBP and BPV during the in-trial period, for the CV endpoints occurring after the end of the trial and (ii) randomly assigned treatment to events following randomization, for the first occurrence of pre-specified CV outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Using BP data from the in-trial period, in the post-trial period, although mean SBP was a predictor of CV outcomes {HR per 10 mmHg, 1.14 [95% confidence interval (CI) 1.10-1.17], P &lt; .001}, systolic BPV independent of mean SBP was a strong predictor of CV events [HR per 5 mmHg 1.22 (95% CI 1.18-1.26), P &lt; .001] and predicted events even in participants with well-controlled BP. During 21-year follow-up, those on amlodipine-based compared with atenolol-based in-trial treatment had significantly reduced risk of stroke [HR 0.82 (95% CI 0.72-0.93), P = .003], total CV events [HR 0.93 (95% CI 0.88-0.98), P = .008], total coronary events [HR 0.92 (95% CI 0.86-0.99), P = .024], and atrial fibrillation [HR 0.91 (95% CI 0.83-0.99), P = .030], with weaker evidence of a difference in CV mortality [HR 0.91 (95% CI 0.82-1.01), P = .073]. There was no significant difference in the incidence of non-fatal myocardial infarction and fatal coronary heart disease, heart failure, and all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Systolic BPV is a strong predictor of CV outcome, even in those with controlled SBP. The long-term benefits of amlodipine-based treatment compared with atenolol-based treatment in reducing CV events appear to be primarily mediated by an effect on systolic BPV during the trial period.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38291599/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38291599</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad814>10.1093/eurheartj/ehad814</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38291599</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Ajay Gupta</dc:creator>
<dc:creator>William N Whiteley</dc:creator>
<dc:creator>Thomas Godec</dc:creator>
<dc:creator>Somayeh Rostamian</dc:creator>
<dc:creator>Cono Ariti</dc:creator>
<dc:creator>Judith Mackay</dc:creator>
<dc:creator>Andrew Whitehouse</dc:creator>
<dc:creator>Leila Janani</dc:creator>
<dc:creator>Neil R Poulter</dc:creator>
<dc:creator>Peter S Sever</dc:creator>
<dc:creator>ASCOT-10 Investigators</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial</dc:title>
<dc:identifier>pmid:38291599</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad814</dc:identifier>
</item>
<item>
<title>Ultra-processed foods and cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38291181/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 30. doi: 10.1038/s41569-024-00990-7. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38291181/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38291181</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00990-7>10.1038/s41569-024-00990-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38291181</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Fernanda Rauber</dc:creator>
<dc:creator>Renata Bertazzi Levy</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Ultra-processed foods and cardiovascular disease</dc:title>
<dc:identifier>pmid:38291181</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00990-7</dc:identifier>
</item>
<item>
<title>A 25-year odyssey of genomic technology advances and structural variant discovery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38290514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>This perspective focuses on advances in genome technology over the last 25 years and their impact on germline variant discovery within the field of human genetics. The field has witnessed tremendous technological advances from microarrays to short-read sequencing and now long-read sequencing. Each technology has provided genome-wide access to different classes of human genetic variation. We are now on the verge of comprehensive variant detection of all forms of variation for the first time with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 23:S0092-8674(24)00004-7. doi: 10.1016/j.cell.2024.01.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This perspective focuses on advances in genome technology over the last 25 years and their impact on germline variant discovery within the field of human genetics. The field has witnessed tremendous technological advances from microarrays to short-read sequencing and now long-read sequencing. Each technology has provided genome-wide access to different classes of human genetic variation. We are now on the verge of comprehensive variant detection of all forms of variation for the first time with a single assay. We predict that this transition will further transform our understanding of human health and biology and, more importantly, provide novel insights into the dynamic mutational processes shaping our genomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38290514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38290514</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.002>10.1016/j.cell.2024.01.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38290514</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>David Porubsky</dc:creator>
<dc:creator>Evan E Eichler</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A 25-year odyssey of genomic technology advances and structural variant discovery</dc:title>
<dc:identifier>pmid:38290514</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.002</dc:identifier>
</item>
<item>
<title>Colchicine to prevent sympathetic denervation after acute myocardial infarction: the COLD-MI trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289979/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehae042. doi: 10.1093/eurheartj/ehae042. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289979/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38289979</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae042>10.1093/eurheartj/ehae042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289979</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Fabien Huet</dc:creator>
<dc:creator>Denis Mariano-Goulart</dc:creator>
<dc:creator>Sylvain Aguilhon</dc:creator>
<dc:creator>Quentin Delbaere</dc:creator>
<dc:creator>Alain Lacampagne</dc:creator>
<dc:creator>Jérémy Fauconnier</dc:creator>
<dc:creator>Florence Leclercq</dc:creator>
<dc:creator>Jean-Christophe Macia</dc:creator>
<dc:creator>Mariama Akodad</dc:creator>
<dc:creator>Nidal Jammoul</dc:creator>
<dc:creator>Fabrice Prunier</dc:creator>
<dc:creator>Nathan Mewton</dc:creator>
<dc:creator>Denis Angoulvant</dc:creator>
<dc:creator>Catherine Lozza</dc:creator>
<dc:creator>Sonia Soltani</dc:creator>
<dc:creator>Annabelle Rodier</dc:creator>
<dc:creator>Sylvie Grandemange</dc:creator>
<dc:creator>Anne-Marie Dupuy</dc:creator>
<dc:creator>Jean-Paul Cristol</dc:creator>
<dc:creator>Mailis Amico</dc:creator>
<dc:creator>Nicolas Nagot</dc:creator>
<dc:creator>François Roubille</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Colchicine to prevent sympathetic denervation after acute myocardial infarction: the COLD-MI trial</dc:title>
<dc:identifier>pmid:38289979</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae042</dc:identifier>
</item>
<item>
<title>Utility of vector flow mapping and [18F]fluorodeoxyglucose-positron emission tomography/computed tomography to assess left ventricular workload in obstructive hypertrophic cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289896/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehae005. doi: 10.1093/eurheartj/ehae005. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289896/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38289896</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae005>10.1093/eurheartj/ehae005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289896</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Nobuhiro Tahara</dc:creator>
<dc:creator>Yoshihiro Fukumoto</dc:creator>
<dc:creator>Eiki Tayama</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Utility of vector flow mapping and [18F]fluorodeoxyglucose-positron emission tomography/computed tomography to assess left ventricular workload in obstructive hypertrophic cardiomyopathy</dc:title>
<dc:identifier>pmid:38289896</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae005</dc:identifier>
</item>
<item>
<title>Electrical storm treatment by percutaneous stellate ganglion block: the STAR study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289867/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240201011053&amp;v=2.18.0
      <description>CONCLUSIONS: The findings of this large, prospective, multicentre study provide evidence in favour of the effectiveness and safety of PSGB for the treatment of refractory ES.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehae021. doi: 10.1093/eurheartj/ehae021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: An electrical storm (ES) is a clinical emergency with a paucity of established treatment options. Despite initial encouraging reports about the safety and effectiveness of percutaneous stellate ganglion block (PSGB), many questions remained unsettled and evidence from a prospective multicentre study was still lacking. For these purposes, the STAR study was designed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a multicentre observational study enrolling patients suffering from an ES refractory to standard treatment from 1 July 2017 to 30 June 2023. The primary outcome was the reduction of treated arrhythmic events by at least 50% comparing the 12 h following PSGB with the 12 h before the procedure. STAR operators were specifically trained to both the anterior anatomical and the lateral ultrasound-guided approach.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 131 patients from 19 centres were enrolled and underwent 184 PSGBs. Patients were mainly male (83.2%) with a median age of 68 (63.8-69.2) years and a depressed left ventricular ejection fraction (25.0 ± 12.3%). The primary outcome was reached in 92% of patients, and the median reduction of arrhythmic episodes between 12 h before and after PSGB was 100% (interquartile range -100% to -92.3%). Arrhythmic episodes requiring treatment were significantly reduced comparing 12 h before the first PSGB with 12 h after the last procedure [six (3-15.8) vs. 0 (0-1), P &lt; .0001] and comparing 1 h before with 1 h after each procedure [2 (0-6) vs. 0 (0-0), P &lt; .001]. One major complication occurred (0.5%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The findings of this large, prospective, multicentre study provide evidence in favour of the effectiveness and safety of PSGB for the treatment of refractory ES.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289867/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240201011053&v=2.18.0">38289867</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae021>10.1093/eurheartj/ehae021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289867</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Simone Savastano</dc:creator>
<dc:creator>Enrico Baldi</dc:creator>
<dc:creator>Sara Compagnoni</dc:creator>
<dc:creator>Roberto Rordorf</dc:creator>
<dc:creator>Antonio Sanzo</dc:creator>
<dc:creator>Francesca Romana Gentile</dc:creator>
<dc:creator>Veronica Dusi</dc:creator>
<dc:creator>Simone Frea</dc:creator>
<dc:creator>Carol Gravinese</dc:creator>
<dc:creator>Filippo Maria Cauti</dc:creator>
<dc:creator>Gianmarco Iannopollo</dc:creator>
<dc:creator>Francesco De Sensi</dc:creator>
<dc:creator>Edoardo Gandolfi</dc:creator>
<dc:creator>Laura Frigerio</dc:creator>
<dc:creator>Pasquale Crea</dc:creator>
<dc:creator>Domenico Zagari</dc:creator>
<dc:creator>Matteo Casula</dc:creator>
<dc:creator>Giuseppe Sangiorgi</dc:creator>
<dc:creator>Simone Persampieri</dc:creator>
<dc:creator>Gabriele Dell'Era</dc:creator>
<dc:creator>Giuseppe Patti</dc:creator>
<dc:creator>Claudia Colombo</dc:creator>
<dc:creator>Giacomo Mugnai</dc:creator>
<dc:creator>Francesco Notaristefano</dc:creator>
<dc:creator>Alberto Barengo</dc:creator>
<dc:creator>Roberta Falcetti</dc:creator>
<dc:creator>Giovanni Battista Perego</dc:creator>
<dc:creator>Giuseppe D'Angelo</dc:creator>
<dc:creator>Nikita Tanese</dc:creator>
<dc:creator>Alessia Currao</dc:creator>
<dc:creator>Vito Sgromo</dc:creator>
<dc:creator>Gaetano Maria De Ferrari</dc:creator>
<dc:creator>STAR study group</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Electrical storm treatment by percutaneous stellate ganglion block: the STAR study</dc:title>
<dc:identifier>pmid:38289867</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae021</dc:identifier>
</item>





























</channel>
</rss>